IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell

Cancer Immunol Res. 2019 Aug;7(8):1258-1266. doi: 10.1158/2326-6066.CIR-18-0711. Epub 2019 Jun 25.

Abstract

Multiple studies have associated the transcription factor IRF1 with tumor-suppressive activities. Here, we report an opposite tumor cell-intrinsic function of IRF1 in promoting tumor growth. IRF1-deficient tumor cells showed reduced tumor growth in MC38 and CT26 colon carcinoma and B16 melanoma mouse models. This reduction in tumor growth was dependent on host CD8+ T cells. Detailed profiling of tumor-infiltrating leukocytes did not show changes in the various T-cell and myeloid cell populations. However, CD8+ T cells that had infiltrated IRF1-deficieint tumors in vivo exhibited enhanced cytotoxicity. IRF1-deficient tumor cells lost the ability to upregulate PD-L1 expression in vitro and in vivo and were more susceptible to T-cell-mediated killing. Induced expression of PD-L1 in IRF1-deficient tumor cells restored tumor growth. These results indicate differential activity of IRF1 in tumor escape.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • B7-H1 Antigen / genetics*
  • B7-H1 Antigen / metabolism
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / metabolism
  • Disease Models, Animal
  • Disease Progression
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Immunologic Memory
  • Immunomodulation* / genetics
  • Interferon Regulatory Factor-1 / genetics
  • Interferon Regulatory Factor-1 / metabolism*
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / metabolism
  • Melanoma, Experimental
  • Mice
  • Mice, Knockout
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • IRF1 protein, human
  • Interferon Regulatory Factor-1